Nanomedicines to treat myocardial infarction: new funds awarded by the FNRS to Jean-Michel Dogné and Julie Laloy

Heart failure represents the first cause of mortality in our country. Up to 15.000 Belgians suffer heart failure every year. Myocardial ischemia-reperfusion injury contributes to the adverse cardiovascular outcomes after myocardial infarction.

Since 2012, Dr. Julie Laloy and Prof. Jean-Michel Dogné (Department of Pharmacy, UNamur) are collaborating with the Université Paris-Sud on the EU-funded project NanoHeart. This project aimed at developing nanoparticles loaded with adenosine to preserve this molecule from rapid degradation, and at demonstrating its cardioprotective effect in vitro and in vivo.

NARILIS researchers have now received a new grant of 450.000 EUR from the FNRS in the framework of the PDR-Thema - Cardiovascular Diseases Call 2019. This funding will allow to pursue the development of innovative multidrug nanomedicines to prevent myocardial ischemia-reperfusion injuries treatment, again in collaboration with their French partners.